ANXA1 and cancer: Moreover, ANXA1 deficiency has been shown to facilitate immune escape in some cancers, including ANXA1-low CRC, by decreasing calreticulin exposure and dendritic cell activation, thus promoting the recruitment of cytotoxic T lymphocytes in TME and resistance to T-cell-induced chemotherapies, such as oxaliplatin [129,187].